News | February 28, 2023
ENHERTU approved in China for patients with HER2 positive metastatic breast cancer treated withantiHER2-based regimens
First approval for Daiichi Sankyo and AstraZeneca’s ENHERTU in China
First approval for Daiichi Sankyo and AstraZeneca’s ENHERTU in China
Submissions based on favorable MagnetisMM-3 trial results in patients with relapsed or refractory multiple myeloma
N-nitroso dimethylamine (NDMA) is a probable human carcinogen and tts effects on humans rely on observational studies.
Clinical studies are expected to start in Q2 2023.
Alkem has submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines.
More than 5 lakh patients availed the benefit of queue-less OPD registration using this service
Ayurveda is one of the most advanced sciences of its times
This artificial RNA ligase has higher thermostability than natural RNA ligase
A total of 889 M&A deals were announced in the medical devices sector in 2022 worth $93 billion
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
Subscribe To Our Newsletter & Stay Updated
